MEK and the inhibitors: from bench to bedside

被引：0
|
作者：
Akintunde Akinleye
Muhammad Furqan
Nikhil Mukhi
Pavan Ravella
Delong Liu
机构：
[1] Westchester Medical Center and New York Medical College,Department of Medicine
[2] New York Medical College and Westchester Medical Center,Division of Hematology and Oncology
来源：
Journal of Hematology & Oncology | / 6卷
关键词：
Melanoma; Docetaxel; Papillary Thyroid Cancer; Malignant Mesothelioma; Vemurafenib;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Four distinct MAP kinase signaling pathways involving 7 MEK enzymes have been identified. MEK1 and MEK2 are the prototype members of MEK family proteins. Several MEK inhibitors are in clinical trials. Trametinib is being evaluated by FDA for the treatment of metastatic melanoma with BRAF V600 mutation. Selumetinib has been studied in combination with docetaxel in phase II randomized trial in previously treated patients with advanced lung cancer. Selumetinib group had better response rate and progression-free survival. This review also summarized new MEK inhibitors in clinical development, including pimasertib, refametinib, PD-0325901, TAK733, MEK162 (ARRY 438162), RO5126766, WX-554, RO4987655 (CH4987655), GDC-0973 (XL518), and AZD8330.
引用
收藏
相关论文
共 50 条
  • [21] Histone deacetylase inhibitors in multiple myeloma: from bench to bedside
    Harada, Takeshi
    Hideshima, Teru
    Anderson, Kenneth C.
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2016, 104 (03) : 300 - 309
  • [22] From bench to bedside - GP IIb-IIIa inhibitors
    Fintel, DJ
    NEUROLOGY, 2001, 57 (05) : S12 - S19
  • [23] The development of PARP inhibitors in ovarian cancer: from bench to bedside
    Drew, Yvette
    BRITISH JOURNAL OF CANCER, 2015, 113 : S3 - S9
  • [24] The Role of mTOR Inhibitors in Hematologic Disease: From Bench to Bedside
    Feng, Yimei
    Chen, Xiaoli
    Cassady, Kaniel
    Zou, Zhongmin
    Yang, Shijie
    Wang, Zheng
    Zhang, Xi
    FRONTIERS IN ONCOLOGY, 2021, 10
  • [25] Thymidylate synthase inhibitors as anticancer agents: from bench to bedside
    Edward Chu
    Marc A. Callender
    Michael P. Farrell
    John C. Schmitz
    Cancer Chemotherapy and Pharmacology, 2003, 52 : 80 - 89
  • [26] Thymidylate synthase inhibitors as anticancer agents: from bench to bedside
    Chu, E
    Callender, MA
    Farrell, MP
    Schmitz, JC
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2003, 52 (Suppl 1) : S80 - S89
  • [27] Cyclin kinase inhibitors in breast cancer: From bench to bedside
    Torres G.
    Echavarría I.
    Lobo M.
    Márquez-Rodas I.
    Martin M.
    Current Breast Cancer Reports, 2014, 6 (2) : 79 - 87
  • [28] Histone deacetylase inhibitors in multiple myeloma: from bench to bedside
    Takeshi Harada
    Teru Hideshima
    Kenneth C. Anderson
    International Journal of Hematology, 2016, 104 : 300 - 309
  • [29] From bench to bedside
    Alberti, A
    JOURNAL OF HEPATOLOGY, 2005, 42 (03) : 301 - 301
  • [30] From Bench to Bedside
    不详
    EUROPEAN HEART JOURNAL, 2018, 39 (32) : 2922 - 2923
12345